TITLE:
Research Progress of Anti-Angiogenic Drugs in First-Line Treatment of Small Cell Lung Cancer
AUTHORS:
Ying Wang, Xi Tang
KEYWORDS:
Anti-Angiogenesis, Small Cell Lung Cancer
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.1,
January
12,
2023
ABSTRACT: Small Cell Lung Cancer (SCLC) is a low-differentiated neuroendocrine tumor with rapid growth, early metastasis and sensitivity to radiotherapy and chemotherapy. It is highly recurrence rate. And there is lacking effective treatment now. As an active research direction at present, anti-angiogenic drugs are not only widely used in non-small cell lung cancer and other tumors, but also have certain effects in small cell lung cancer combined with chemotherapy. As one of the effective treatment methods for small cell lung cancer, related research is not rare, but there is still inadequacy, such as side effects can not be tolerated, and the timing of treatment can not be accurately assessed. This article will briefly describe the research progress of anti-angiogenic drugs combined with chemotherapy in the first-line treatment of extensive small cell lung cancer.